Clinical Evaluation of PET-CT for Staging of Colorectal Lung Metastases

Metastatic Colorectal Cancer Clinical Trial

Official title:

Clinical Evaluation of PET-CT for Staging of Colorectal Lung Metastases - a Prospective Monocentric Feasibility Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02942901
• Other study ID #: Oskar Helene 11/2016
• Status: Completed
• Start date: January 2015
• Est. completion date: January 1, 2020

Study information

• Verified date: September 2020
• Source: Lung Clinic Heckeshorn
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Surgery has been available for the treatment of pulmonary metastases in metastatic colorectal cancer and promising overall survival was observed in retrospective studies with selected patients. This study investigated whether the preoperative FDG- PET/CT scan influences survival in this patient group. Furthermore, we tried to identify other prognostic factors associated with overall survival and progression-free survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: January 1, 2020
• Est. primary completion date: September 1, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients over 18 years with pulmonary metastases eligible for pulmonary metastasectomy

Exclusion Criteria:

• Second primary cancer within the last 2 years (exception basal cell carcinoma of the skin)

• Pregnancy,

• Drug addiction,

• Renal dialysis

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer
• Neoplasm Metastasis

Intervention

Procedure:
• PET-CT

Locations

Country	Name	City	State
Germany	Lung Clinic Heckeshorn at HELIOS Hospital Emil von Behring	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
Lung Clinic Heckeshorn

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Pastorino U, Veronesi G, Landoni C, Leon M, Picchio M, Solli PG, Leo F, Spaggiari L, Pelosi G, Bellomi M, Fazio F. Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis. J Thorac Cardiovasc Surg. 2003 Dec;126(6):1906-10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival		5 years
Secondary	Number and sites of metastases detected by PET-CT		3 years